RxDoctor Payments DataLook up a doctor →

Andrea Mattison, PA

Medical · Kenosha, WINPI 1902852072

Payments from drug & device makers

$13,698in general payments, 2019–2025

Across 673 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$929
  • Pfizer$659
  • E.r. Squibb & Sons, L.L.C.$587
  • plus $6K from 37 others

What the payments were for

  • Food & beverage$13,61699%
  • Education$821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,698 in reported general payments places this provider in the 95th percentile of 247 medical providers in Wisconsin.

See all medical providers in Wisconsin

Medicare billing

Part B allowed, 2024
$42,652
Medicare patients
217
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$104,087
JardianceEmpagliflozin45$70,132
EliquisApixaban26$41,225
XareltoRivaroxaban20$25,717
FarxigaDapagliflozin Propanediol19$24,401
MounjaroTirzepatide13$18,702
SynthroidLevothyroxine Sodium29$3,239
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$3,011
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,474
Levothyroxine Sodium211$2,120
Rosuvastatin Calcium162$1,871
Albuterol Sulfate HfaAlbuterol Sulfate40$1,702
Metoprolol Succinate112$1,568
Lisinopril177$1,326
Calcitonin-SalmonCalcitonin,salmon,synthetic14$1,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,348$104,08760 claims
Boehringer IngelheimJardiance$278$70,13245 claims
PfizerEliquis$659$41,22526 claims
Johnson & JohnsonXarelto$85$25,71720 claims
AstraZenecaFarxiga$2,545$24,40119 claims
Lilly USA, LLCMounjaro$929$18,70213 claims
AbbVieSynthroid$1,475$3,23929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 medical providers in Wisconsin.

Other medical in Kenosha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →